Form 4 for OMCL OMNICELL, INC.
Accepted 2025-12-03 00:00:00 ET · period of report 2025-12-01 · accession 0001227556-25-000007 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-12-03 | 2025-12-01 | OMCL | LIPPS RANDALL A | COB, Pres AND CEO, Dir | S - Sale+OE | $35.97 | -28.2K | 386.6K | -7% | -$1.02M |
| D | 2025-12-03 | 2025-12-01 | OMCL | LIPPS RANDALL A | COB, Pres AND CEO, Dir | M - OptEx | $27.70 | +28.2K | 414.9K | +7% | +$782.5K |
| D | 2025-12-03 | 2025-12-01 | OMCL | LIPPS RANDALL A | COB, Pres AND CEO, Dir | M - OptEx | $0.00 | -28.2K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-01 | S | D | 28,250 | $35.97 | 386,648 | D | — | — | (F1) This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2025. (F2) The price reported in Column 4 is a weighted average price of $35.9679. The sold price range between $35.65 to $36.4746. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2025-12-01 | M | A | 28,250 | $27.70 | 414,898 | D | — | — | (F1) This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2025. |
| 3 | Derivative | Stock Option NQ (Right to Buy) | 2025-12-01 | M | D | 28,250 | $0.00 | 0 | D | $27.70 · — to 2026-02-04 | 28,250 Common Stock | (F1) This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2025. (F5) The options were granted on 2/4/2016 with 25% vested on the one-year anniversary of the grant date and the reaming amount vesting ratably over a 36 month period. The options were fully vested on 2/4/2020. |